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Introduction
Mortality from cancer, the second leading cause of death
worldwide, remains unacceptably high. From 1975 to 2000,
the total number of cancer cases worldwide rose from 5.9 mil-
lion to 10 million, an increase of 69% (1). Although advances
in the early detection of tumors and in the use of chemotherapy
and surgery for disease management have helped to enhance
the overall survival of afflicted patients, major improvements
in treatments for most human cancers are urgently needed. The
control and therapy of cancer may benefit from introduction of
new treatments derived from natural products (2). Between
1974 and 1994, it is estimated that about 67% of pharmaceuti-
cal products approved for human cancer therapy were derived
from natural sources. The discovery of efficacious compounds
for cancer management will benefit from new understanding
of the molecular and cellular pathways that regulate tumor pro-
liferation and progression.
Advance Access Publication 9 February 2005 eCAM 2005;2(1)49–57
doi:10.1093/ecam/neh066
© The Author (2005). Published by Oxford University Press. All rights reserved.
Review
Antiangiogenic Steroids in Human Cancer Therapy
Richard J. Pietras and Olga K. Weinberg
David Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology-Oncology,
Los Angeles, CA, USA
Despite advances in the early detection of tumors and in the use of chemotherapy, radiotherapy and
surgery for disease management, the worldwide mortality from human cancer remains unacceptably
high. The treatment of cancer may benefit from the introduction of novel therapies derived from natural
products. Natural products have served to provide a basis for many of the pharmaceutical agents in
current use in cancer therapy. Emerging research indicates that progressive growth and spread of many
solid tumors depends, in part, on the formation of an adequate blood supply, and this process of tumor-
associated angiogenesis is reported to have prognostic significance in several human cancers. This
review focuses on the potential application in antitumor therapy of naturally-occurring steroids that
target tumor-associated angiogenesis. Squalamine, a 7,24 dihydroxylated 24-sulfated cholestane steroid
conjugated to a spermidine at position C-3, is known to have strong antiangiogenic activity in vitro, and
it significantly disrupts tumor proliferation and progression in laboratory studies. Work on the interac-
tions of squalamine with vascular endothelial cells indicate that it binds with cell membranes, inhibits
the membrane Na/H exchanger and may further function as a calmodulin chaperone. These primary
actions appear to promote inhibition of several vital steps in angiogenesis, such as blockade of mitogen-
induced actin polymerization, cell–cell adhesion and cell migration, leading to suppression of endothe-
lial cell proliferation. Preclinical studies with squalamine have shown additive benefits in tumor growth
delay when squalamine is combined with cisplatin, paclitaxel, cyclophosphamide, genistein or radiation
therapy. This compound has also been assessed in early phase clinical trials in cancer; squalamine was
found to exhibit little systemic toxicity and was generally well tolerated by treated patients with various
solid tumor malignancies, including ovarian, non-small cell lung and breast cancers. Clinical trials with
squalamine alone or combined with standard chemotherapies or other biologic therapies, including
antiangiogenic agents, should be considered for selected cancer patients, and further study of the
mechanism of action and bioactivity of squalamine is warranted.
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The progressive growth and spread of many solid tumors
depends, in part, on the formation of an adequate blood supply,
and tumor angiogenesis has been reported to have prognostic
significance in several human cancers (3). Therapy directed
toward the vasculature of solid tumors is now being pursued as
an important new direction in cancer treatment because avascu-
lar tumors exhibit only limited growth and tumor aggressive-
ness, and metastatic potential commonly correlates with tumor
vascularity (4–7). Vascular endothelial growth factor (VEGF) is
produced by most solid tumors and elicits a mitogenic effect
on tumor-associated endothelial cells (8,9). VEGF binding to
receptor tyrosine kinases triggers activation of downstream
signaling enzymes, including MAP kinase, which, in turn, reg-
ulate gene expression and specific endothelial cell responses
including proliferation, migration and apoptosis (10–12).
Several studies have suggested that VEGF plays an important
role in the progression of many cancers (3,13,14). Growth
factor pathways, such as those dependent on EGF and HER-2
receptors, appear to up-regulate VEGF production in solid
tumors (15,16). Since EGF and HER family receptors are acti-
vated (17,18) and/or overexpressed in significant numbers of
human cancers (18–21), these growth factor receptor pathways
may play a role in promoting further growth of human malig-
nancy by increasing VEGF-dependent tumor angiogenesis.
Antiangiogenic Steroids in Cancer Therapy
Many small molecules, proteins and antibodies directed to
growth factors have been identified as having antiangiogenic
activity. Several steroids were among the first molecules
recognized as having antiangiogenic activity. These compounds
included progestin, medroxyprogesterone acetate and gluco-
corticoids such as dexamethasone and cortisone (6,7). Such
angiostatic steroids appear to have multiple and diverse effects
on tumor-associated angiogenesis, including the inhibition of
endothelial cell proliferation, the inhibition of collagenolysis
and of plasminogen activator production, as well as direct anti-
tumor activity amongst some malignancies. However, the activ-
ity of these compounds was characterized primarily by their
ability to prevent new blood vessel growth in the chick embryo
allantoic membrane assay system for angiogenesis. The most
potent of these antiangiogenic steroids, 11-hydrocortisone
and tetrahydrocortisol, lacked mineralocorticoid or glucocorti-
coid activity and produced capillary regression in the chick
embryo allantoic membrane assay (22).
Later, using tumor models in animals, several antiangiogenic
steroids exhibited measurable activity that was often enhanced
when the steroid was given in combination with heparin or a
heparin-like molecule (22–24). Of these antiangiogenic
steroids, only medroxyprogesterone was assessed in clinical
trials, primarily in patients with previously treated breast can-
cer (25). Study endpoints of partial or complete tumor
responses showed only minimal clinical activity and no exten-
sion of survival.
An endogenous metabolite of estrogen, 2-methoxyestradiol,
has been found to inhibit proliferation, migration and invasion of
endothelial cells in vitro as well as having antiangiogenic effects
in certain in vivo tumor models (26). The mechanism of action
of this compound is not yet fully elucidated, but its action does
not seem to be mediated by classical steroid hormone receptors.
Recent evidence has shown that 2-methoxyestradiol inhibits
HIF-1, a key angiogenic transcription factor, and is, thus, able
to elicit a broad spectrum of cellular effects. This activity
appeared to correlate with microtubule-depolymerizing proper-
ties of 2-methoxyestradiol. This steroidal compound is also
reported to initiate apoptosis in both vascular endothelial and
solid tumor cells. In preclinical models, 2-methoxyestradiol
reduced tumor size and tumor-associated vascularization. In
early clinical trials, this agent appears to be well tolerated by
patients with cancer, and use of 2-methoxyestradiol is currently
being evaluated in several different types of malignancy (26).
Squalamine, a natural steroidal compound initially found in
several tissues of the dogfish shark, Squalus acanthias, causes
changes in vascular endothelial cell shape and has been
reported to possess significant antiangiogenic activity in mod-
els of lung, breast, brain and ovarian cancer (22,27,28). In the
shark, squalamine is found primarily in sites of bile synthesis
such as liver and gallbladder, but the aminosterol compound
also occurs in smaller amounts in the spleen, testes, stomach,
gills and intestine (29). In the laboratory, squalamine was orig-
inally found to have bactericidal activity against gram-negative
and gram-positive bacteria, as well as some fungicidal quali-
ties (29). More importantly, squalamine at relatively low doses
was later shown to selectively inhibit the formation of new
blood vessels. However, unlike previously described steroids,
squalamine has significant structural differences and does not
interact with glucocorticoid or minealocorticoid receptors
(30). It is a 7,24 dihydroxylated 24-sulfated cholestane steroid
conjugated to a spermidine at position C-3 (see Fig. 1).
Squalamine has been demonstrated to be an angiostatic steroid
by virtue of its inhibition of growth of vascular endothelial
cells in culture, activity in the chick embryo chorioallantoic
membrane assay and a rabbit corneal micropocket assay, as
well as growth inhibition of gliomas and lung cancers in vivo
(22,28,31). Squalamine is somewhat unique among most cur-
rent anti-angiogenic agents in development because it inhibits
endothelial cell proliferation and migration induced by a wide
variety of growth factors, including Basic Fibroblast Growth
Factor (bFGF) and VEGF (27,31; Fig. 2). This broad antiangio-
genic activity of squalamine may result from its inhibition of sur-
face sodium–proton exchangers (thus altering intracellular pH
and thereby impeding intracellular signaling by several growth
factors) and other downstream signaling pathways in endothelial
cells (27,29). There are different theories about the mechanism of
action of squalamine that remain to be investigated.
Mechanism of Action of Squalamine
One mechanism of action of squalamine has been proposed by
Akhter et al. (32) to involve inhibition of the mammalian
brush-border Na/H exchanger isoform NHE3. The Na/H
exchanger is a transport protein that is known to regulate
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changes in cell volume or cell shape. Using transfected PS120
fibroblasts, the investigators found that inhibitory effects of
squalamine on Na/H exchanger activity were both time and
concentration dependent and reversible. The effect of the
steroidal compound was measured as changes in intracellular
pH, specifically Na-dependent alkalinization of the cell inte-
rior was inhibited by exposure to squalamine. Inhibition of
Na/H exchange, as opposed to another mechanism of pH
regulation, was confirmed by independent monitoring of 22Na
uptake by cells. This effect of squalamine was found to be
specific for NHE3, as it did not affect NHE1, NHE2, Na-
dependent D-glucose uptake or Na-independent D-glucose
uptake. To rule out that inhibitory effects of squalamine were
not due to cytotoxicity, Lactate Dehydrogenase (LDH) release
was also measured and found to be 5% of total cell LDH.
Using a truncated mutant of NHE3, this study also showed that
inhibition of NHE3 required the C-terminal 76 amino acids of
NHE3. This region of NHE3 is a critical part of the enzyme
regulatory domain, with external control by calmodulin,
calmodulin-kinase II, tyrosine kinases and squalamine. The
inhibitory effect of calmodulin on NHE3 appears to be medi-
ated through these 76 C-terminal amino acids as well.
However, it remains undetermined if squalamine inhibition of
NHE3 requires interaction with other regulatory molecules.
Nonetheless, squalamine regulation of intracellular pH could
have a major impact on the activity of other signaling path-
ways in target cells such as vascular endothelial cells.
Squalamine has also been proposed to be a calmodulin chap-
eron by Chen et al. (33). In efforts to isolate and partially
purify squalamine-binding components from human placenta,
Chen et al. determined the direct association of squalamine
with calmodulin. Indeed, specific interactions between calmod-
ulin and squalamine occurred for both forms of calmodulin,
calcium-free and calcium-bound. Further, exposure of human
vascular endothelial cells to fluorescent-tagged squalamine
revealed a rapid relocalization of calmodulin and squalamine
from the cell periphery to the perinuclear endosomal compart-
ment. After squalamine treatment, F-actin stress fibers were
disrupted and a change in cell shape was noted. Based on these
observations, the authors proposed that the mechanism of action
of squalamine involved its specific entry into endothelial
cells, leading to the intracellular redistribution of calmodulin
without inhibition of calmodulin function.
The biologic actions of squalamine were assessed further by
Sills et al. (28). In this work, squalamine was found to inhibit
rat brain endothelial cell proliferation and migration induced
by mitogens such as VEGF, bFGF, Platelet Derived Growth
Factor (PDGF), and scatter factor/hepatocyte growth factor. In
the absence of these mitogens, squalamine was found to have
no direct effect on survival or proliferation of endothelial cells.
 
 
 
  
   
 
 
  
 
 
  
 
  
 
  
  
 
  
 
 
  
Figure 1. Squalamine, a 7,24 dihydroxylated 24-sulfated cholestane steroid conjugated to a spermidine at position C-3. This steroidal compound was initially
found in tissues of dogfish shark, Squalus acanthias, primarily in sites of bile synthesis such as liver and gallbladder. However, squalamine also occurs in spleen,
testes, stomach, gills and intestine. See text for additional details.
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Figure 2. Models of tumor-associated angiogenesis in human solid tumors.
Cancer cells with growth factor receptors (e.g. EGFR, HER-2) secrete
endothelial cell growth factors that stimulate vascular endothelial cell growth
factor (VEGF) receptors (4). Both peptide and steroid regulation of blood ves-
sel growth may involve MAPK pathways that regulate the cytoskeleton and
cell proliferation (53). Squalamine may interact with cell surface proton
pumps, calmodulin or other signaling pathways, possibly localized in caveolae-
related lipid rafts (27,29,32), to block activation of MAP kinases in blood
endothelial cells. See text for details.
In addition, squalamine was also found to inhibit proton secre-
tion by mitogen-stimulated endothelial cells, a finding consis-
tent with results reported by Akhter et al. (32). An interesting
finding of this study involved the direct application of
squalamine to 4-day-old chick embryo vasculature. After only
20 min, squalamine elicited constriction of the smallest capil-
laries throughout the yolk sac, with entrapment of red cells. In
addition, the usual continuous blood flow through large vessels
was changed to a pulsatile expansion in order to move through
occluded vessels. This acute remodeling process resulted in
narrowed vascular segments and blocked erythrocyte move-
ment and was confirmed by histological examination of treated
and untreated yolk sacs. Since these new vessels are composed
solely of endothelial cells, the luminal narrowing was con-
cluded to be due to squalamine-induced changes in the shape
or volume of endothelial cells. This study also established that
systemic treatment with squalamine promoted an inhibition of
the growth of rat flank 9L glioma tumors. Immunohistochemical
analyses of these tumors after treatment with squalamine
revealed significant reductions in tumor-associated blood-
vessel density.
In order to further understand the molecular and cellular
mechanisms by which squalamine inhibits tumor growth,
Williams et al. (34) evaluated the effects of squalamine on the
organization of the endothelial cell actin cytoskeleton and
transmembrane cell–cell adhesion elements. Human vascular
endothelial cells were grown and stimulated with VEGF and
then treated with squalamine. The results showed that
squalamine disrupted polymerization of F-actin fibers in these
cells. In addition, after squalamine treatment, it was found that
significantly less VE-cadherin was detectable at the endothe-
lial cell–cell junction, with apparent increments in peri-nuclear
VE-cadherin. This suggested that squalamine induced an inter-
nalization process that involves moving VE-cadherin from the
membrane into the intracellular compartment. VE-cadherin is
a member of the cadherin family that is involved in cell–cell
adherence junction maintenance and is also associated with
actin filament attachment sites on the cell surface. These find-
ings led the authors to conclude that squalamine perturbs both
actin polymerization and cell–cell adhesion in endothelial
cells. Thus, squalamine interferes with the ability of endothe-
lial cells to move, grow and communicate, thus inhibiting the
formation of new vessels. This process may be very important
in preventing the nourishment and progression of tumors.
Li et al. (15) conducted studies of human ovarian tumor-
associated angiogenesis. Ovarian cells were found to secrete
significant levels of VEGF, a direct activator of angiogenesis
(see Fig. 2), but squalamine did not reduce VEGF secretion by
tumor cells, and it evoked no direct growth inhibition of
ovarian cells in vitro. However, squalamine at doses as low as
160 nM did halt the proliferation of human vascular endothe-
lial cells and markedly reduced VEGF-induced capillary tube-
like formations by vascular endothelial cells growing in
Matrigel culture (35). These biologic effects correlated well
with squalamine-induced blockade of the rapid VEGF-stimu-
lated phosphorylation of p44/p42 MAP kinase in endothelial
cells, an early cell response to activate proliferation. VEGF is
considered to exert its biologic effects by binding with recep-
tor tyrosine kinases, notably Flt-1 and Flk-1/KDR, present at
the surface of endothelial cells (36,37). Post-receptor signal
transduction regulates the effects of VEGF (see Fig. 2), and
the proliferative action of VEGF in endothelial cells has been
associated, in part, with VEGF-induced tyrosine phosphoryla-
tion and stimulation of MAP kinase, ERK-1 (p44) and ERK-2
(p42) (10,37). Of note, squalamine also reduced VEGF-
induced phosphorylation of focal adhesion kinase (FAK) and
stress-activated protein kinase-2/p38 SAPK2, blocking, in
turn, assembly of F-actin stress fibers in vascular endothelial
cells. These effects follow primary interaction of squalamine
with caveolar domains at the surface membranes of endothe-
lial cells, sites for the concentration of vital signaling com-
plexes to regulate the angiogenic process (37). Squalamine
interference with these downstream signaling pathways in
vascular endothelial cells may be critical in disrupting the
process of tumor-associated angiogenesis.
Preclinical Studies with Squalamine
Studies by Teicher et al. (22) noted that squalamine as a single
agent has a modest effect on tumor growth delay on rat 13762
mammary carcinoma, with squalamine dosing at 40 mg/kg.
Combining squalamine with cyclophosphamide, cisplatin or
paclitaxel increased the tumor growth delay by 1.9–2.5-fold as
compared to any of these agents administered alone. A Lewis
lung carcinoma was a second tumor model examined in this
study. The lung tumor model allowed squalamine effects on
primary and metastatic disease to be evaluated since untreated
mice generally die from metastatic tumor spread by days
21–25. Squalamine alone had a modest effect on tumor growth
delay, but, again, an additive effect was seen when squalamine
was combined with cyclophosphamide, cisplatin, paclitaxel or
5-fluorouracil. Moreover, it was found that the number of
lung metastases decreased when mice were treated with
squalamine. Specifically, by day 20, the numbers of metastases
were reduced to half of those present in controls. Since lung
metastases are actively implanting and growing using new
blood vessels, this effect of squalamine suggests that it has
strong antiangiogenic potency.
Using non-small cell lung tumor models, Williams and
colleagues (34) assessed the effect of squalamine alone and
combined with either cisplatin or paclitaxel with carboplatin.
Chemotherapy-resistant MV-522 tumor cells were implanted
as xenografts in immunodeficient mice and allowed to reach a
size of about 60 mg. Squalamine was administered alone at
dose of 20 mg/kg/day or in combination with cisplatin (dose of
2 mg/kg/day) or as a part of triple therapy with paclitaxel
(10 mg/kg/day) and carboplatin (20 mg/kg/day). The results
indicated that squalamine either combined with cisplatin
or included as a part of triple therapy with paclitaxel and
carboplatin was more effective than administration alone in
suppressing the growth of MV-522 human lung tumors. Final
excised mice tumor weight after treatment with squalamine
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alone was 613.6  64.6 mg, while treatment with squalamine
and cisplatin resulted in final tumor weights of 105.0 
28.6 mg. When administered as a part of triple therapy with
paclitaxel and carboplatin, the final excised mice tumor weight
was 56.4  14.5 mg. The effect of adding squalamine to other
treatments was found to persist throughout the experiment.
The antitumor effects of squalamine with and without cyto-
toxic agents were examined in other human lung cancer
xenografts by Schiller and Bittner (38). The cell lines used
included Calu-6 (adenocarcinoma), H460 (large cell carcinoma),
NL20T-A (derived from an immortalized human bronchial
epithelial cell line that underwent spontaneous transformation
to a tumorigenic phenotype) and Lewis lung. Squalamine
appeared to have no cytotoxic effect in vitro on lung cell lines,
and addition of squalamine to cisplatin did not result in
enhanced death of tumor cells. In vivo, squalamine alone was
effective in reducing tumor formation only when administ-
ered before, simultaneously, or 24 h after inoculation of mice
with tumor cells. When combined with platinum analogs,
squalamine resulted in 1.5–2-fold growth delay of tumors in
all four lung cell lines. No antitumor activity was seen
when squalamine was combined with paclitaxel, venorelbine,
gemcitabine or docetaxel. Multiple doses of cisplatin and
squalamine increased tumor growth delay more than a single
dose. Using H460 tumor xenografts, the effects of squalamine
on tumor vascularization were determined. As a single agent,
squalamine had no effect on the number of CD31-staining
vessels in established tumors. However, when used in combi-
nation with cisplatin, the number of vessels was reduced
by 25%. This effect was observed early (within 2–4 h after
treatment) and dissipated by 48 h. These results suggest that
squalamine and platinum analogs likely need to be adminis-
tered together in close temporal proximity.
In studies of human non-small cell lung tumors grown as
xenografts in nude mice, our laboratory has further assessed
the effects of squalamine treatment alone and combined with
either the phytoestrogen, genistein, or radiation therapy (see
Fig. 3). The non-small cell lung tumor, NCI-H23, as many
human lung tumors, is enriched with estrogen receptor- and
this receptor signaling pathway may also promote angiogenesis
(39). Treatment with squalamine alone elicits a modest inhibi-
tion of the growth of human non-small cell lung tumor cells
NCI-H23 (P  0.05). Moreover, combination of squalamine
with genistein (Fig. 3A), a potential inhibitor of estrogen
receptor- activity, appears to elicit additive antitumor effects
that exceed the responses to single agent treatments (P 
0.001). In addition, squalamine was combined with radiation
therapy, a common treatment intervention for non-small cell
lung cancer, and this combination was highly effective in sup-
pressing tumor growth (P  0.001) (Fig. 3B). This latter find-
ing supports independent data suggesting that the combination
of ionizing radiation with antiangiogenic agents can improve
tumor eradication, possibly without increasing deleterious
effects (40).
Squalamine’s effect on breast cancer was studied by Williams
et al. (41). MX-1 breast xenografts were grown in mice and
were treated with Cytoxan (cyclophosphamide). After tumor
regression, mice were randomized into control and squalamine-
treated groups. Two different doses of squalamine were used
(10 and 20 mg/kg/day) and both resulted in increased numbers
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Figure 3. Squalamine inhibits growth of human non-small cell lung tumor cells and enhances the antitumor effects of radiation therapy and genistein. Lung can-
cers with estrogen receptor- and estrogen receptor- expression (NCI-H23) were grown as subcutaneous xenografts to 50–100 mm3 in size in ovariectomized,
nude mice primed with estrogen (1.7 mg/pellet). Mice were then treated as outlined here. (A) Genistein, a phytoestrogen, and squalamine inhibit growth of human
lung tumor xenografts NCI-H23 in nude mice. Mice with established tumors were treated with control solution, genistein alone (0.2 mg/kg s.c. on alternate days)
(18), squalamine alone (2 mg/kg s.c.) on days 1–10, or genistein with squalamine. By 28 days, tumors showed little tumor regression after treatment with genis-
tein alone and modest regression after squalamine alone compared to control (P  0.05). More profound tumor growth inhibition was elicited by treatment with
squalamine plus genistein (P  0.001). Mean tumor volumes of control (CON), genistein (G), squalamine (SQ) and combined squalamine/genistein (SQ/G) treat-
ment are shown. (B) Radiation therapy (RT) and squalamine inhibit growth of lung tumor xenografts NCI-H23 in nude mice. Mean tumor volumes of control
(CON), RT (4 Gy on days 1, 4 and 7), squalamine (SQ; 2 mg/kg s.c. on days 1–10) and combined squalamine/RT (SQ/RT) treatment are shown. See Pietras et al.
(54,55) and text for details.
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of tumors which underwent complete regression. The authors
conclude that squalamine influences the latent period for tumor
expansion post effective chemotherapy.
Previous studies have suggested that VEGF plays an import-
ant role in progression of ovarian cancer (15). Ovarian cancer is
the most deadly gynecologic malignancy (42–45). Although
advances in chemotherapy and surgery have helped to improve
the overall survival of afflicted patients, 5-year survival rates
from ovarian cancer remained about 44% in the early part of this
decade. By the time many patients are diagnosed with ovarian
cancer, peritoneal dissemination of the tumor has often
occurred. This growth and spread of ovarian cancers depends,
in part, on formation of an adequate blood supply. Tumor-
associated angiogenesis is essential for growth of most solid
tumors, and neovascularization has also been shown to have
prognostic significance in epithelial ovarian cancer (3). Several
studies have shown that VEGF expression plays an important
role in the progression of ovarian cancers (3,13,14), and the fur-
ther ability of VEGF to increase vascular permeability (4,8,46)
may contribute to formation of malignant ascites in patients with
ovarian cancer (47). It is possible that treatment strategies
directed to suppress the expression of VEGF and related angio-
genic molecules may help to block tumor progression and
reduce the morbidity associated with malignant ascites. Since
squalamine has been shown to inhibit endothelial proliferation
by mitogens such as VEGF, the effect of squalamine on ovarian
cancer was examined by Li et al. (15). Using human ovarian
OV2008 cells with HER-2 overexpression grown as xenografts
in mice, the authors were able to show profound tumor growth
inhibition by combined treatment with squalamine and cisplatin
(see Fig. 4). This growth inhibition persisted for 18 days after
stopping squalamine treatment. This study showed that the
length of tumor growth delay was greatest with the combined
treatment of squalamine and cisplatin as compared with the
effects of single-agent therapy.
The molecular effects of squalamine and cisplatin were also
assessed by evaluating levels of tumor cell apoptosis.
Administration of squalamine in combination with cisplatin led
to enhanced levels of apoptosis in several ovarian tumor cells
assessed in vivo. The extent of tumor cell death was higher with
the combination treatment than with either squalamine or cis-
platin administered alone. The findings suggest that squalamine
enhances the cytotoxicity of cisplatin chemotherapy by facili-
tating tumor cell apoptosis. Using immunohistochemical
methods to assess tumor-associated blood vessel density, the
investigators were able to show that squalamine caused a reduc-
tion of tumor-associated angiogenesis in different types of
ovarian tumors.
Clinical Studies with Squalamine
On the basis of strong evidence of antiangiogenic and antitu-
mor properties of squalamine, it was selected for clinical devel-
opment as a therapeutic agent for treatment of human
malignancies. The squalamine in use in these and more recent
clinical trials is synthesized in a pharmaceutical facility (48).
A phase I study was conducted by Bhargava et al. (49) to deter-
mine the maximum tolerated dose (MTD), dose-limiting toxic-
ities (DLTs) and the pharmacokinetic profile of squalamine.
The investigators recruited 19 patients with an Eastern
Cooperative Oncology Group (ECOG) performance status of
≤ 2 with advanced non-leukemic cancers. Squalamine was
administered as a continuous intravenous infusion over 120 h,
with repeat dosing every 14 days. The starting dose was chosen
as 6 mg/m2/day, increasing at a rate of 100% up to a dose of
384 mg/m2/day, after which it was escalated in 40% increments
until DLT was encountered. The highest dose administered was
538 mg/m2/day. The best-tolerated dose of squalamine was
found to be 192 mg/m2/day, although a dose of 384 mg/m2/day
also appeared to be well-tolerated in patients without prior
exposure to squalamine. Three or more patients were treated at
each dose level. In the absence of toxicity during the first treat-
ment cycle, patients were allowed to have their doses escalated.
This reduced the time to reach the MTD, with less patients
required to start at lower doses. The DLT noted with
squalamine administration was hepatotoxicity, measured as
abnormalities in liver function tests and mostly noted to occur
at the highest dose of 538 mg/m2/day. However, the hepatotox-
icity was found to be transient and reversible. Mild to moderate
fatigue was also noted in all patients at all dose levels, and this
resolved after treatment. Plasma pharmacokinetics from this
study showed that squalamine has a short initial elimination
half-life and a high plasma clearance. The area under the con-
centration-time curve (AUC0–t) and the maximum concentra-
tion (Cmax) of squalamine was found to be dose and dose-rate
proportional over 12–384 mg/m2/day, with evidence of nonlin-
earity at 538 mg/m2/day. Clearance of squalamine was also
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Figure 4. Squalamine promotes the time to tumor progression in a human
ovarian tumor xenograft model in vivo. CAOV3 ovarian cancer cells were
inoculated subcutaneously in nude mice as before (15). After 7 days, animals
with tumors of comparable size were randomized to treatment with con-
trol solution (CON), squalamine (SQ; 2 mg/kg on days 1–10), cisplatin (Pt;
4 mg/kg on day 1), or cisplatin administered in combination with squalamine
(SQ/Pt). Tumor volumes (mm3) are expressed as mean  SEM for measure-
ments to assess tumor growth delay due to the several treatments. Data derived
from Li et al. (15), with permission.
unchanged at all doses. Transient tumor regression was
observed in some patients treated with squalamine, but all
patients had overall progression of their disease. The investiga-
tors emphasize that all patients in this trial had advanced malig-
nant disease, while antiangiogenic treatments are hypothesized
to work best in individuals with minimal disease burden. In
addition, maximal squalamine effects are most likely obtained
when combined with chemotherapy drugs as demonstrated in
preclinical studies. In general, the treatment with squalamine
was well-tolerated by patients.
Another phase I and pharmacokinetic study of squalamine
was reported by Hao et al. (50). They recruited 33 patients with
advanced solid tumor malignancies. Squalamine was adminis-
tered as a 5-day continuous intravenous infusion that was
repeated every 3 weeks. The starting dose was 6 mg/m2/day, and
dose levels were escalated in 40% increments. The maximal
dose administered was 700 mg/m2/day. The main DLT in this
trial was also found to be elevations in hepatic transaminases
and hyperbilirubinemia. At a dose of 700 mg/m2/day, two out
of three patients developed grade 4 hyperbilirubinemia and
grade 3 or 4 elevations in hepatic transaminases. Based on these
results, the authors concluded that the recommended dose of
squalamine should not exceed 500 mg/m2/day as a continuous
intravenous infusion over 5 days every 3 weeks. This study
evaluated a larger number of patients in the 357–700 mg/m2
dose range, as compared to the previous phase I study by allow-
ing a different definition for DLT (e.g. grade 3 or 4 transaminase
elevation lasting 7 days). This also led to somewhat different
findings on squalamine kinetics. Squalamine was shown to
exhibit dose-proportional kinetics in this study, whereas
Bhargava et al. (49) concluded that AUC0–t and Cmax were
nonlinear at the highest dose. With the 12–15-week treatments,
stable disease was noted in some of the test patients, but no
major tumor regressions were observed.
Since squalamine has shown evidence of additive or syner-
gistic antitumor activity with certain cytotoxic chemothe-
urapeutic agents, a phase I/IIA study was designed by Herbst
et al. (51) to examine the antitumor efficacy of squalamine in
combination with carboplatin and paclitaxel in patients with a
diagnosis of non-small cell lung cancer. The primary goal of
this study was to examine safety, clinical response and phar-
macokinetics of squalamine when administered as a 5-day
continuous infusion in combination with standard chemother-
apy in patients with stage IIIB or stage IV non-small cell lung
cancers. With 45 patient volunteers, squalamine was adminis-
tered as 5-day continuous intravenous infusion ranging from
100 to 400 mg/m2/day repeated every 21 days for one cycle, at
which point an evaluation of DLT was made. In the absence
of DLT, dose escalation was permitted by 100 mg/m2/day.
Paclitaxel was administered at a dose of 225 mg/m2 as a 3-h
i.v. infusion, followed by carboplatin and followed by
squalamine. After one patient at the 400 mg/m2 dose experi-
enced significant DLT, it was determined that 300 mg/m2/day
was the MTD for squalamine to be used in the phase II study.
This dose was administered for up to six 21-day cycles.
Importantly, significant toxicities in this study were limited to
mild myelosuppresion. This study showed that squalamine
exhibited linear pharmacokinetics, and plasma clearance of
squalamine did not change at the doses used. Moreover, the
pharmacokinetic profile of paclitaxel was not changed by com-
bining the chemotherapy drug with squalamine. Similarly,
carboplatin drug clearance was not changed by squalamine.
With regard to antitumor efficacy endpoints, a partial clinical
response was obtained in 28% of evaluable patients. Stable
disease was shown in 19% of patients, while disease progres-
sion occurred in 53% of patients. Thus, significant clinical
benefit was observed for 47% of evaluable patients with
advanced stage non-small cell lung cancer. In the group of
patients who were treated at the MTD of 300 mg/m2/day,
median survival was 8.5 months, and 1-year survival was 33%.
To assess the antitumor efficacy of squalamine in human
ovarian cancer, a phase II clinical study was performed by
Davidson et al. (52). On recruiting 33 patients with stage III or
stage IV ovarian cancer who were resistant or refractory to
platinum-based chemotherapy, squalamine was administered
with carboplatin as a 5-day continuous infusion at a dose of
200 mg/m2/day. Average treatment time was 81 days. Response
data have been reported for 22 patients, and, among this group,
eight patients had an objective clinical response. Major toxic-
ity reported in this study among three patients was grade 4
thrombocytopenia, anemia, leukopenia, myalgia or asthenia,
symptoms often associated with carboplatin chemotherapy.
Additional patients were enrolled in the study, but the final
data remain to be presented (52). Nonetheless, these results
suggest that squalamine may be a significant addition to cur-
rent treatment options for patients with advanced refractory
ovarian cancers. Based on currently-available information on
the potential antitumor efficacy of squalamine in ovarian
cancer, the antiangiogenic steroid has been designated an
‘orphan drug’ candidate for future therapeutic development in
ovarian malignancy, a group for whom new treatment alterna-
tives are urgently needed.
Conclusions
Natural products have served to provide a basis for many of
the pharmaceutical agents in current use in cancer therapy and
prevention. Squalamine, a natural steroidal compound, causes
changes in vascular endothelial cell shape, and has been
reported to possess significant antiangiogenic activity in mod-
els of lung, breast, brain and ovarian cancer. The mechanism
of action has also been proposed to involve inhibition of
endothelial cell proliferation and migration induced by mito-
gens in addition to being a calmodulin chaperone (28,33).
Preclinical studies with squalamine have shown that it is more
effective in tumor growth delay when combined with radiation
therapy, genistein, cisplatin, paclitaxel and cyclophosphamide.
In addition, studies using Lewis lung carcinoma found that the
number of metastasis were reduced by half after treatment,
which confirms the antiangiogenic potency of squalamine.
Squalamine exhibited little systemic toxicity in Phase I–II
clinical trials and is well tolerated by treated cancer patients
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(49,50,52). Pending positive results in future randomized,
controlled clinical trials of antitumor efficacy, squalamine has
the potential to become a useful addition to the clinical options
available for patients with solid tumor malignancies, such as
ovarian, non-small cell lung and breast cancers. Clinical trials
with squalamine alone or combined with standard chemother-
apies or other biologic therapies, including antiangiogenic
agents, should be considered for selected cancer patients. The
US Food and Drug Administration has designated squalamine
as an ‘orphan drug’ for development as a new antitumor agent
to treat ovarian cancer, and further study of its mechanism of
action and bioactivity is warranted. The development of
squalamine as an antitumor pharmaceutical provides yet
another example of how a natural product can help to elucidate
novel approaches to the treatment of disease.
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